Reuters logo
6 months ago
BRIEF-Gemphire Therapeutics expands utility for Gemcabene
January 9, 2017 / 1:28 PM / 6 months ago

BRIEF-Gemphire Therapeutics expands utility for Gemcabene

1 Min Read

Jan 9 (Reuters) - Gemphire Therapeutics Inc

* Expanded utility for gemcabene demonstrate proof of concept efficacy in animal model of nonalcoholic steatohepatitis

* Plans to initiate clinical development of Gemcabene in nash/nonalcoholic fatty liver disease (NAFLD) with a phase 2 trial (Azure-1) in 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below